ClinicalTrials.gg

Program

eloralintide

Also written as “Eloralintide”, “LY3841136” and “eloralintide and tirzepatide”.

Its studies are mostly in Obesity · Osteoarthritis · Sleep Apnea, Obstructive · Kidney Failure, Chronic · Hepatic Insufficiency, led by Eli Lilly.

Furthest: phase 3, since Dec 5, 202526 company-led studies, 19 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly2619 open or runningphase 3since Dec 5, 2025Mar 24, 2022Dec 2026phase 1 · NCT07738614
  • Named in Eli Lilly’s own pipeline as Eloralintide, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Mar 24, 2022.

  1. Mar 1, 20242 phase 1 studies in ObesityNCT06297616, NCT06345066
  2. Sep 17, 2024Phase 2 study in ObesityNCT06603571 · 367 enrolled · United States, Argentina
  3. Apr 1, 20252 phase 1 studiesNCT06916091, NCT06916065
  4. Oct 9, 2025Phase 2 study in ObesityNCT07215559 · 200 enrolled · United States, Argentina, Australia and more
  5. Dec 5, 2025Phase 3 study in OverweightPhase 3 reachedNCT07282600 · 1,035 planned · United States, China, Czechia and more
  6. Jan 5, 20264 phase 3 studiesNCT07321886, NCT07353931, NCT07369011 and 1 more
  7. Feb 4, 20262 phase 1 studiesNCT07401862, NCT07426380
  8. May 11, 2026Phase 2 study in OverweightNCT07589608 · 400 planned · United States
  9. Jun 19, 2026Phase 1 study in OverweightNCT07665879 · 115 planned · Germany, Sweden
  10. Jul 9, 20262 phase 1 studiesNCT07701083, NCT07738614
  11. Aug 11, 2026Phase 1 study in ObesityNCT07765511 · 60 planned · Japan
  12. Sep 3, 2026Phase 1 study in ObesityNCT07808060 · 34 planned · United States
  13. Oct 12, 20263 phase 3 studies in ObesityNCT07881458, NCT07881432, NCT07900633
  14. Nov 9, 2026Phase 1 study in HealthyNCT07935304 · 90 planned · United States, Singapore

Ahead

  1. Dec 2026Primary completion: phase 1 study in ObesityNCT07738614
  2. Mar 2027Primary completion: phase 1 study in Hepatic InsufficiencyNCT07401862
  3. Mar 2027Primary completion: phase 2 study in ObesityNCT07215559
  4. Apr 2027Primary completion: phase 1 study in HealthyNCT07935304

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07935304Healthy · United States, Singapore1Not yet recruitingApr 202790
NCT07900633Obesity · United States, Argentina, Australia and more3Not yet recruitingNov 20293,000
NCT07881458Obesity · United States, Brazil, China and more3RecruitingOct 20291,000
NCT07881432Obesity · United States, Argentina, China and more3Not yet recruitingOct 20292,115
NCT07808060Obesity · United States1RecruitingJun 202734
NCT07765511Obesity · Japan1Not yet recruitingJun 202760
NCT07738614Obesity · United States, Singapore1RecruitingDec 202656
NCT07701083Healthy Volunteers · United States1Active, not recruitingOct 202658
NCT07665879Overweight · Germany, Sweden1RecruitingAug 2027115
NCT07589608Overweight · United States2RecruitingSep 2027400
NCT07426380Kidney Diseases · United States1Active, not recruitingOct 202628
NCT07401862Hepatic Insufficiency · United States, Hungary1RecruitingMar 202736
NCT07392190Overweight · United States, Australia, Belgium and more3RecruitingJun 2028900
NCT07369011Sleep Apnea, Obstructive · United States, Australia, Brazil and more3RecruitingMar 2028800
NCT07353931Osteoarthritis · United States, Argentina, Belgium and more3RecruitingMar 2028900
NCT07321886Obesity · United States, Argentina, Australia and more3RecruitingMar 20281,980
NCT07282600Overweight · United States, China, Czechia and more3RecruitingJan 20281,035
NCT07215559Obesity · United States, Argentina, Australia and more2Active, not recruitingMar 2027200
NCT06916091Obesity · Singapore1CompletedSep 9, 202530
NCT06916065Overweight · United States1CompletedJan 19, 2026188
NCT06603571Obesity · United States, Argentina2CompletedJul 1, 2026367
NCT06345066Obesity · United States1CompletedSep 29, 202596
NCT06297616Obesity · Japan1CompletedNov 21, 2025128
NCT06230523Obesity · United States2CompletedMay 30, 2025263
NCT06143956Obesity · United States, Argentina2RecruitingSep 20271,481
NCT05295940Obesity · United States1CompletedJan 25, 2024148

How it is read

Names in the registry

  • “Eloralintide”, 19 entries
  • “LY3841136”, 7 entries
  • “eloralintide and tirzepatide”, 2 entries
  • “Eloralintide and Tirzepatide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.